Safety of repeated yttrium-90 radioembolization

CardioVascular and Interventional Radiology

Volumn 36, Issue 5, 2013, Pages 1320-1328

  Lam, Marnix G E H ^a,b   Louie, John D ^a   Iagaru, Andrei H ^a   Goris, Michael L ^a   Sze, Daniel Y ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Liver; Radiation; Radioembolization; Repeated treatment; Safety; Toxicity

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GLASS; RESIN; YTTRIUM 90;

ADULT; AGED; ANEMIA; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT CARCINOMA; BILIRUBIN BLOOD LEVEL; CHEMOEMBOLIZATION; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COLON CANCER; COLORECTAL CARCINOMA; DEATH; DRUG DELIVERY SYSTEM; DRUG FATALITY; EMBOLIC PARTICLE; FATIGUE; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; KIDNEY CARCINOMA; LARGE CELL NEUROENDOCRINE CARCINOMA; LEIOMYOSARCOMA; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER INJURY; LIVER METASTASIS; MALE; METASTASIS; MULTIVARIATE ANALYSIS; NAUSEA; PAIN; PORTAL HYPERTENSION; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; RADIATION INJURY; RADIATION SAFETY; RADIOEMBOLIZATION; RADIOEMBOLIZATION INDUCED LIVER DISEASE; REPEATED RADIOEMBOLIZATION INDUCED LIVER DISEASE; RETREATMENT; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; SYMPTOM; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; VOMITING;

AGED; BRACHYTHERAPY; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; ODDS RATIO; RADIATION INJURIES; RETREATMENT; RETROSPECTIVE STUDIES; RISK FACTORS; YTTRIUM RADIOISOTOPES;

EID: 84884673489     PISSN: 01741551     EISSN: 1432086X     Source Type: Journal    
DOI: 10.1007/s00270-013-0547-9     Document Type: Article

References (21)

1. Coldwell D, Sangro B, Salem R et al (2012) Radioembolization in the treatment of unresectable liver tumors: experience across a range of primary cancers. Am J Clin Oncol 35:167-177
2. Sangro B, Salem R, Kennedy A et al (2011) Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations. Am J Clin Oncol 34:422-431
3. Vente MA, Wondergem M, van de Tweel et al (2009) Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol 19:951-959
4. 90Y microsphere brachytherapy in the treatment of hepatic malignancies. Med Phys 38:4824-4845
5. 90Y microspheres: angiographic and technical considerations. Cardiovasc Interv Radiol 30:571-592
6. 90Y- microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 74:1494-1500
7. Murthy R, Brown DB, Salem R et al (2007) Gastrointestinal complications associated with hepatic arterial yttrium-90 microsphere therapy. J Vasc Interv Radiol 18:553-561
8. Salem R, Parikh P, Atassi B et al (2008) Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol 31:431-438
9. Coldwell D, Sangro B, Wasan H et al (2011) General selection criteria of patients for radioembolization of liver tumors: an international working group report. Am J Clin Oncol 34:337-341
10. Riaz A, Lewandowski RJ, Kulik LM et al (2009) Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol 20:1121-1130
11. Sangro B, Gil-Alzugaray B, Rodriguez J et al (2008) Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 112:1538-1546
12. Lawrence TS, Robertson JM, Anscher MS et al (1995) Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 31:1237-1248
13. Abdelmaksoud M, Chang D, Eclov NC et al (2011) Safety of Y90 radioembolization in patients who have undergone previous external beam radiotherapy (abstract). J Vasc Interv Radiol 22:S201
14. Kennedy A, Nag S, Salem R et al (2007) Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the Radioembolization Brachytherapy Oncology Consortium. Int J Radiat Oncol Biol Phys 68:13-23
15. Siddiqi NH, Devlin PM (2009) Radiation lobectomy-a minimally invasive treatment model for liver cancer: case report. J Vasc Interv Radiol 20:664-669
16. van Persijn, van Meerten EL, Gelderblom H, Bloem JL (2010) RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol 20:1456-1467
17. Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50:122S-150S
18. Borgelt BB, Gelber R, Brady LW et al (1981) The palliation of hepatic metastases: results of the Radiation Therapy Oncology Group pilot study. Int J Radiat Oncol Biol Phys 7:587-591
19. Russell AH, Clyde C, Wasserman TH et al (1993) Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the RTOG dose escalating protocol. Int J Radiat Oncol Biol Phys 27:117-123
20. Hall EJ (1988) Time dose and fractionation in radiotherapy. In: Radiobiology for the Radiologist. Lippincott, Philadelphia, pp 240-259
21. Goin JE, Salem R, Carr BI et al (2005) Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 16:205-213